Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Drug Development for Alzheimer’s and Parkinson’s Disease: Where Do We Go Now?

Lisa Sequeira
,
Sofia Benfeito
ORCID logo ,
Carlos Fernandes
,
Alexandra Gaspar
,
Inês Lima
,
Joana Peixoto
,
Catarina Alves
,
Cláudia Sofia Machado
,
Fernanda Borges
* ORCID logo ,
Daniel Chavarria
*
Version 1 : Received: 5 April 2024 / Approved: 5 April 2024 / Online: 5 April 2024 (12:39:57 CEST)

How to cite: Sequeira, L.; Benfeito, S.; Fernandes, C.; Gaspar, A.; Lima, I.; Peixoto, J.; Alves, C.; Machado, C.S.; Borges, F.; Chavarria, D. Drug Development for Alzheimer’s and Parkinson’s Disease: Where Do We Go Now?. Preprints 2024, 2024040437. https://doi.org/10.20944/preprints202404.0437.v1 Sequeira, L.; Benfeito, S.; Fernandes, C.; Gaspar, A.; Lima, I.; Peixoto, J.; Alves, C.; Machado, C.S.; Borges, F.; Chavarria, D. Drug Development for Alzheimer’s and Parkinson’s Disease: Where Do We Go Now?. Preprints 2024, 2024040437. https://doi.org/10.20944/preprints202404.0437.v1

Abstract

Neurodegenerative diseases (NDs) are a set of progressive, chronic, and incurable diseases characterized by the gradual loss of neurons, culminating in the decline of cognitive and/or motor functions. Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the most common NDs and represent an enormous burden both in terms of human suffering and economic cost. The available therapies for AD and PD only provide symptomatic and palliative relief for a limited period and are unable to modify the diseases’ progression. Over the last decades, research efforts have been focused on developing new pharmacological treatments for these NDs. However, to date, no breakthrough treatment has been discovered. Hence, the development of disease-modifying drugs able to halt or reverse the progression of NDs remains an unmet clinical need. This review summarizes the major hallmarks of AD and PD and the drugs available for pharmacological treatment. It also sheds light on potential directions that can be pursued to develop of new, disease-modifying drugs to treat AD and PD, thereby decreasing the social and economic burdens linked to these NDs.

Keywords

neurodegenerative diseases; Parkinson’s disease; Alzheimer’s disease; drug discovery; disease-modifying drugs

Subject

Chemistry and Materials Science, Medicinal Chemistry

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.